Visual Recovery of Dysthyroid Optic Neuropathy With Teprotumumab

Affiliations

¹ Department of Ophthalmology (MJL, JLH, DAT), Medical College of Georgia, Augusta University, Augusta, Georgia; and Franklin College of Arts and Sciences (CT), University of Georgia, Athens, Georgia.

Michael J Lopez et al. J Neuroophthalmol. 2022.

. 2022 Jun 1;42(2):e491-e493.

doi: 10.1097/WNO.0000000000001298. Epub 2021 Jun 25.

¹ Department of Ophthalmology (MJL, JLH, DAT), Medical College of Georgia, Augusta University, Augusta, Georgia; and Franklin College of Arts and Sciences (CT), University of Georgia, Athens, Georgia.

No abstract available

Conflict of interest statement

The authors report no conflict of interest.

1. Blandford AD, Zhang D, Chundury RV, Perry JD. Dysthyroid optic neuropathy: update on pathogenesis, diagnosis, and management. Expert Rev Ophthalmol. 2017;12:111–121.
1. Taylor PN, Zhang L, Lee RWJ, Muller I, Ezra DG, Dayan CM, Kahaly GJ, Ludgate M. New insights into the pathogenesis and nonsurgical management of Graves orbitopathy. Nat Rev Endocrinol. 2020;16:104–116.
1. Douglas RS, Kahaly GJ, Patel A, Sile S, Thompson EHZ, Perdok R, Fleming JC, Fowler BT, Marcocci C, Marinò M, Antonelli A, Dailey R, Harris GJ, Eckstein A, Schiffman J, Tang R, Nelson C, Salvi M, Wester S, Sherman JW, Vescio T, Holt RJ, Smith TJ. Teprotumumab for the treatment of active thyroid eye disease. N Engl J Med. 2020;382:341–352.
1. Sears CM, Azad AD, Dosiou C, Kossler AL. Teprotumumab for dysthyroid optic neuropathy: early response to therapy. Ophthalmic Plast Reconstr Surg. 2020.